IMBCR & Emory University’s Big Discovery!
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…
read moreEfficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020
January 19, 2021 WEST HOLLYWOOD, CA, January 19, 2021 – ONCOtherapeutics and Dr. James Berenson…
read moreJames R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…
read moreSerum BCMA to Determine Disease Progression in RRMM Patients
Serum BCMA to Determine Disease Progression in RRMM Patients Sponsor: Incyte Protocol Number: I-RUX-19-52 Start…
read moreA Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are…
read moreA Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women
A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care…
read moreNeoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab
Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab Sponsor: Merck/Cedars-Sinai Protocol Number: 2018-04-McArthur-neoHP Start Date: 11/15/2019…
read moreA Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to…
read moreA Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide,…
read moreA Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Sponsor: Incyte Protocol…
read more